Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeshi Hashimoto

Showing results (301-310 of 319) with videos related to

Pageof 32
Sort By:
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 4, 2026
Network oscillatory dynamics accompany cerebral bioenergetic defence in hypoxiaDamian M Bailey, Benjamin S Stacey, Yaopeng Ma, et al.
Molecular Cytogenetics|July 3, 2015
Assessment of copy number variations in the brain genome of schizophrenia patientsMiwako Sakai, Yuichiro Watanabe, Toshiyuki Someya, et al.
Nature Communications|April 26, 2018
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancerMichael R McDevitt, Daniel L J Thorek, Takeshi Hashimoto, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
Cancers|November 26, 2022
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Takaya Ohno, Kazumasa Komura, et al.
Cancer Medicine|September 14, 2023
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancerTakuya Tsujino, Satoshi Tokushige, Kazumasa Komura, et al.
Clinical Genitourinary Cancer|October 25, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, et al.
Pageof 32

Showing results (301-310 of 319) with videos related to

Sort By:
Pageof 32
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 4, 2026
Network oscillatory dynamics accompany cerebral bioenergetic defence in hypoxiaDamian M Bailey, Benjamin S Stacey, Yaopeng Ma, et al.
Molecular Cytogenetics|July 3, 2015
Assessment of copy number variations in the brain genome of schizophrenia patientsMiwako Sakai, Yuichiro Watanabe, Toshiyuki Someya, et al.
Nature Communications|April 26, 2018
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancerMichael R McDevitt, Daniel L J Thorek, Takeshi Hashimoto, et al.
Urologic Oncology|July 31, 2024
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safetyTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
BJU International|September 13, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinomaTaizo Uchimoto, Tatsuo Fukushima, Kazumasa Komura, et al.
Clinical and Translational Radiation Oncology|December 22, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Shogo Yamazaki, Kazumasa Komura, et al.
Cancers|November 26, 2022
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Takaya Ohno, Kazumasa Komura, et al.
Cancer Medicine|September 14, 2023
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancerTakuya Tsujino, Satoshi Tokushige, Kazumasa Komura, et al.
Clinical Genitourinary Cancer|October 25, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Kiyoshi Takahara, Atsuhiko Yoshizawa, et al.
Pageof 32